| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | AUY922 | GDSC1000 | pan-cancer | AAC | 0.066 | 0.08 |
| mRNA | Oxaliplatin | CTRPv2 | pan-cancer | AAC | -0.064 | 0.09 |
| mRNA | birinapant | CTRPv2 | pan-cancer | AAC | 0.072 | 0.09 |
| mRNA | BYL-719 | CTRPv2 | pan-cancer | AAC | -0.079 | 0.09 |
| mRNA | GDC-0941 | CTRPv2 | pan-cancer | AAC | -0.068 | 0.09 |
| mRNA | YK 4-279 | GDSC1000 | pan-cancer | AAC | 0.069 | 0.09 |
| mRNA | lenvatinib | CTRPv2 | pan-cancer | AAC | -0.067 | 0.09 |
| mRNA | salermide:PLX-4032 (12:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.07 | 0.09 |
| mRNA | Bortezomib | CTRPv2 | pan-cancer | AAC | 0.065 | 0.09 |
| mRNA | Curcumin | CTRPv2 | pan-cancer | AAC | 0.063 | 0.1 |